Phase II Study of Venetoclax Added to Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed by Consolidation With Cladribine Plus LDAC Alternating With 5-Azacitidine With Venetoclax in Patients With Untreated AML
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Cladribine (Primary) ; Cytarabine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 06 Nov 2019 Results (n=26) from this study, were released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 05 Jun 2019 Planned End Date changed from 3 Jan 2020 to 3 Jan 2021.
- 06 Nov 2018 Planned End Date changed from 31 Jan 2020 to 3 Jan 2020.